Arrowhead Pharmaceuticals Inc
ARWR29.075USD
+1.075+3.84%
Handelsschluss 09/05, 16:00（ET）Kurse um 15 Minuten verzögert
4.02BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Arrowhead Pharmaceuticals Inc Unternehmen
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.
Unternehmensinformationen
BörsenkürzelARWR
Name des UnternehmensArrowhead Pharmaceuticals Inc
IPO-datumDec 14, 1993
CEODr. Christopher Richard (Chris) Anzalone, Ph.D.
Anzahl der mitarbeiter609
WertpapierartOrdinary Share
GeschäftsjahresendeDec 14
Addresse177 E Colorado Blvd
StadtPASADENA
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl91105
Telefon16266964702
Websitehttps://arrowheadpharma.com/
BörsenkürzelARWR
IPO-datumDec 14, 1993
CEODr. Christopher Richard (Chris) Anzalone, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.92M
-3.47%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
527.20K
+13.53%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
131.49K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
77.51K
-2.39%
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
47.16K
-6.45%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
38.40K
--
Ms. Victoria (Vicki) Vakiener
Ms. Victoria (Vicki) Vakiener
Independent Director
Independent Director
37.94K
+0.01%
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Independent Director
Independent Director
35.78K
-2.60%
Mr. Daniel Apel
Mr. Daniel Apel
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Vincent Anzalone
Mr. Vincent Anzalone
Investor Relations
Investor Relations
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.92M
-3.47%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
527.20K
+13.53%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
131.49K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
77.51K
-2.39%
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
47.16K
-6.45%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
38.40K
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sun, Aug 17
Aktualisiert: Sun, Aug 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
12.73%
The Vanguard Group, Inc.
11.21%
Avoro Capital Advisors LLC
7.67%
State Street Global Advisors (US)
4.61%
Slate Path Capital LP
3.78%
Andere
60.00%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
12.73%
The Vanguard Group, Inc.
11.21%
Avoro Capital Advisors LLC
7.67%
State Street Global Advisors (US)
4.61%
Slate Path Capital LP
3.78%
Andere
60.00%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
41.14%
Investment Advisor/Hedge Fund
23.06%
Hedge Fund
7.19%
Individual Investor
4.44%
Research Firm
2.60%
Sovereign Wealth Fund
1.39%
Bank and Trust
0.96%
Pension Fund
0.95%
Venture Capital
0.18%
Andere
18.08%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
583
126.42M
91.54%
+6.47M
2025Q1
603
125.23M
90.71%
+6.54M
2024Q4
609
108.09M
85.81%
-8.58M
2024Q3
605
106.83M
85.95%
-7.44M
2024Q2
608
107.20M
86.35%
-5.57M
2024Q1
621
105.82M
85.63%
+13.72M
2023Q4
625
87.51M
81.46%
-1.31M
2023Q3
624
83.79M
78.09%
-822.40K
2023Q2
641
80.82M
75.59%
-4.71M
2023Q1
648
81.64M
75.46%
-182.63K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
18.18M
13.17%
+3.66M
+25.22%
Mar 31, 2025
The Vanguard Group, Inc.
13.18M
9.54%
+1.02M
+8.37%
Mar 31, 2025
Avoro Capital Advisors LLC
11.11M
8.05%
--
--
Mar 31, 2025
State Street Global Advisors (US)
7.00M
5.07%
+983.02K
+16.34%
Mar 31, 2025
Slate Path Capital LP
5.23M
3.79%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
3.32M
2.4%
-1.74M
-34.40%
Mar 31, 2025
Anzalone (Christopher Richard)
3.92M
2.84%
-141.12K
-3.47%
Apr 11, 2025
Geode Capital Management, L.L.C.
2.95M
2.14%
-4.63K
-0.16%
Mar 31, 2025
Invus Public Equities Advisors, LLC
2.67M
1.93%
-231.80K
-7.99%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Sep 2
Aktualisiert: Tue, Sep 2
Name
Anteil
Invesco Biotechnology & Genome ETF
2.8%
Global X Genomics & Biotechnology ETF
2.22%
ROBO Global Healthcare Technology & Innovation ETF
1.58%
Invesco S&P SmallCap Health Care ETF
1.34%
ALPS Medical Breakthroughs ETF
1.31%
Virtus LifeSci Biotech Clinical Trials ETF
1.15%
Tema Heart & Health ETF
1.02%
SPDR S&P Biotech ETF
0.56%
WisdomTree BioRevolution Fund
0.45%
Invesco NASDAQ Future Gen 200 ETF
0.44%
Mehr Anzeigen
Invesco Biotechnology & Genome ETF
Anteil2.8%
Global X Genomics & Biotechnology ETF
Anteil2.22%
ROBO Global Healthcare Technology & Innovation ETF
Anteil1.58%
Invesco S&P SmallCap Health Care ETF
Anteil1.34%
ALPS Medical Breakthroughs ETF
Anteil1.31%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil1.15%
Tema Heart & Health ETF
Anteil1.02%
SPDR S&P Biotech ETF
Anteil0.56%
WisdomTree BioRevolution Fund
Anteil0.45%
Invesco NASDAQ Future Gen 200 ETF
Anteil0.44%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
